- EXBLIFEP demonstrated superiority in the primary endpoint of clinical cure and microbiological eradication at test-of-cure over piperacillin-tazobactam
- EXBLIFEP safety profile was comparable to piperacillin-tazobactam
SAINT-LOUIS, France and WEIL AM RHEIN, Germany, Feb. 25, 2020 (GLOBE NEWSWIRE) — Allecra Therapeutics today announced that its investigational product EXBLIFEP (cefepime-enmetazobactam) met the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) pre-specified primary endpoint in the Phase 3 ALLIUM clinical trial in patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). In addition, EXBLIFEP demonstrated superiority over piperacillin-tazobactam.
Full PR available here